Until recently, we were focused on the research and development of novel therapeutics for neurodegenerative diseases, such as Niemann Pick disease type C (NPC).
In May 2022, substantially all our assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.
Company announcement No. 10/2023 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 C o penhagen, Denmark, May 19 , 202 3 – Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to
Company announcement Orphazyme A/S No. 09/2023 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Major shareholder announcement C o penhagen, Denmark, May 17 , 202 3 – Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of
Company announcement Orphazyme A/S No. 8/2023 Ole Maaløes Vej 3 DK-2200 Copenhagen N
